- Conditions
- Colorectal Adenocarcinoma
- Interventions
- Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Dietary Supplement · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1027
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 676 more
Location Directory
Clinical trials in Denver, Colorado
This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7457
Shown on this page
12
Current sort
Recently updated
Location scope
Denver, CO
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 433–444 of 7,457 matching trials in Denver, CO.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Systemic Sclerosis
- Interventions
- Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1, Nerandomilast formulation 2
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Interventions
- Darlifarnib, Cabozantinib, Adagrasib
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
- Conditions
- Fabry Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 9,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2034
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more
- Conditions
- Glycogen Storage Disease Type Ia
- Interventions
- No Intervention
- Other
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 9
- States / cities
- Orange, California • Denver, Colorado • Hartford, Connecticut + 6 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- sparsentan, irbesartan, Dapagliflozin
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Zasocitinib, Active Comparator, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,088 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 51
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 45 more
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 88
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
- Conditions
- Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 12,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2034
- U.S. locations
- 86
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Endometrial Cancer
- Interventions
- Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation
- Radiation · Other
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 77
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 61 more
- Conditions
- Type B Aortic Dissection
- Interventions
- TEVAR, Guideline directed medical therapy and surveillance of dissection
- Procedure · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- Solid Tumor
- Interventions
- Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 20 more